Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_2

60%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(3)

Detailed Status

Completed2

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (40.0%)

Phase 23 (60.0%)

Trials by Status

completed240%

terminated240%

withdrawn120%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_2

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

NCT02016534

Clinical Trials (5)

Showing 5 of 5 trials

NCT03132155Phase 2

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

Terminated

NCT01253707Phase 1

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Completed

NCT02096666Phase 1

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Completed

NCT03147976Phase 2

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

Withdrawn

NCT02016534Phase 2

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5